BioCentury

10:27 PM GMT, Nov 6, 2018
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Finance

Advancing AlzeCure

Stockholm-based AlzeCure Pharma AB is planning to raise SEK200 million ($22 million) in an IPO on NASDAQ First North Premier to bring both arms of its Alzheimer’s disease portfolio to the clinic.

In a prospectus filed on Nov. 6, the company announced

Read the full 423 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.